
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4490891/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics, 2015, 47, 458-468.	21.4	729
2	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 66-77.	1.2	225
3	Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Therapy, 2010, 17, 1363-1371.	4.5	107
4	The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. PLoS ONE, 2011, 6, e23332.	2.5	95
5	Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumor Biology, 2014, 35, 5911-5920.	1.8	95
6	CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. Cancer Immunology Research, 2016, 4, 259-268.	3.4	90
7	Benefits of interferon $\hat{\mathfrak{e}}^{\hat{l}^2}$ and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter. Cancer, 2011, 117, 1721-1730.	4.1	85
8	Intraoperative subcortical mapping of a language-associated deep frontal tract connecting the superior frontal gyrus to Broca's area in the dominant hemisphere of patients with glioma. Journal of Neurosurgery, 2015, 122, 1390-1396.	1.6	79
9	Evaluation of Resting State Networks in Patients with Gliomas: Connectivity Changes in the Unaffected Side and Its Relation to Cognitive Function. PLoS ONE, 2015, 10, e0118072.	2.5	73
10	Girdin maintains the stemness of glioblastoma stem cells. Oncogene, 2012, 31, 2715-2724.	5.9	67
11	The Modulation of MicroRNAs by Type I IFN through the Activation of Signal Transducers and Activators of Transcription 3 in Human Glioma. Molecular Cancer Research, 2009, 7, 2022-2030.	3.4	58
12	Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Cancer Gene Therapy, 2015, 22, 487-495.	4.6	56
13	Glioma-initiating cells and molecular pathology: implications for therapy. Brain Tumor Pathology, 2011, 28, 1-12.	1.7	55
14	Retrovirally engineered Tâ€cellâ€based immunotherapy targeting type III variant epidermal growth factor receptor, a gliomaâ€associated antigen. Cancer Science, 2010, 101, 2518-2524.	3.9	53
15	Association of dorsal inferior frontooccipital fasciculus fibers in the deep parietal lobe with both reading and writing processes: a brain mapping study. Journal of Neurosurgery, 2014, 121, 142-148.	1.6	53
16	Lack of presence of the human cytomegalovirus in human glioblastoma. Modern Pathology, 2014, 27, 922-929.	5.5	47
17	Surgical benefits of combined awake craniotomy and intraoperative magnetic resonance imaging for gliomas associated with eloquent areas. Journal of Neurosurgery, 2017, 127, 790-797.	1.6	45
18	Immunohistochemical analysisâ€based proteomic subclassification of newly diagnosed glioblastomas. Cancer Science, 2012, 103, 1871-1879.	3.9	42

#	Article	IF	CITATIONS
19	<i><scp>MET</scp></i> Gain in Diffuse Astrocytomas is Associated with Poorer Outcome. Brain Pathology, 2013, 23, 13-18.	4.1	37
20	Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas undergoing intraoperative awake brain mapping. Journal of Neurosurgery, 2020, 132, 1683-1691.	1.6	37
21	Interferon-β Delivery via Human Neural Stem Cell Abates Glial Scar Formation in Spinal Cord Injury. Cell Transplantation, 2013, 22, 2187-2201.	2.5	30
22	Supratotal Resection of Diffuse Frontal Lower Grade Gliomas with Awake Brain Mapping, Preserving Motor, Language, and Neurocognitive Functions. World Neurosurgery, 2018, 119, 30-39.	1.3	29
23	Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. Cancer Gene Therapy, 2012, 19, 796-801.	4.6	27
24	Urinary MicroRNA-Based Diagnostic Model for Central Nervous System Tumors Using Nanowire Scaffolds. ACS Applied Materials & Interfaces, 2021, 13, 17316-17329.	8.0	27
25	Newly established patient-derived organoid model of intracranial meningioma. Neuro-Oncology, 2021, 23, 1936-1948.	1.2	26
26	Epigenetic aberrations and therapeutic implications in gliomas. Cancer Science, 2010, 101, 1331-1336.	3.9	25
27	Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leukemia and Lymphoma, 2011, 52, 2069-2075.	1.3	25
28	Rhabdoid glioblastoma in a child: case report and literature review. Brain Tumor Pathology, 2011, 28, 65-70.	1.7	23
29	Anterior insular cortex stimulation and its effects on emotion recognition. Brain Structure and Function, 2019, 224, 2167-2181.	2.3	23
30	The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro-Oncology, 2023, 25, 326-336.	1.2	23
31	Assessment of Tumor Cells in a Mouse Model of Diffuse Infiltrative Glioma by Raman Spectroscopy. BioMed Research International, 2014, 2014, 1-8.	1.9	21
32	A free-radical scavenger protects the neural progenitor cells in the dentate subgranular zone of the hippocampus from cell death after X-irradiation. Neuroscience Letters, 2010, 485, 65-70.	2.1	20
33	Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. Cancer Chemotherapy and Pharmacology, 2014, 73, 53-60.	2.3	20
34	Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. Radiotherapy and Oncology, 2018, 129, 347-351.	0.6	18
35	A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. Brain Tumor Pathology, 2017, 34, 91-97.	1.7	16
36	Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Brain Tumor Pathology, 2018, 35, 106-113.	1.7	16

#	Article	IF	CITATIONS
37	Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping. Journal of Neuro-Oncology, 2021, 153, 361-372.	2.9	16
38	DMBT1Homozygous Deletion in Diffuse Astrocytomas Is Associated With Unfavorable Clinical Outcome. Journal of Neuropathology and Experimental Neurology, 2012, 71, 702-707.	1.7	15
39	Correlation between quantified promoter methylation and enzymatic activity of O 6-methylguanine-DNA methyltransferase in glioblastomas. Tumor Biology, 2012, 33, 373-381.	1.8	15
40	Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness. Journal of Neuropathology and Experimental Neurology, 2015, 74, 704-709.	1.7	14
41	A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR. Brain Tumor Pathology, 2018, 35, 97-105.	1.7	14
42	H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant. Acta Neuropathologica Communications, 2020, 8, 8.	5.2	14
43	<i>PDGFRA</i> Gain in Low-Grade Diffuse Gliomas. Journal of Neuropathology and Experimental Neurology, 2013, 72, 61-66.	1.7	13
44	Navigated repetitive transcranial magnetic stimulation as preoperative assessment in patients with brain tumors. Scientific Reports, 2020, 10, 9044.	3.3	13
45	Applicable advances in the molecular pathology of glioblastoma. Brain Tumor Pathology, 2015, 32, 153-162.	1.7	12
46	An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. Science and Technology of Advanced Materials, 2016, 17, 618-625.	6.1	12
47	Efficacy of the transtemporal approach with awake brain mapping to reach the dominant posteromedial temporal lesions. Acta Neurochirurgica, 2017, 159, 177-184.	1.7	12
48	Effects of insular resection on interactions between cardiac interoception and emotion recognition. Cortex, 2021, 137, 271-281.	2.4	12
49	Preoperative predictive factors affecting return to work in patients with gliomas undergoing awake brain mapping. Journal of Neuro-Oncology, 2020, 146, 195-205.	2.9	11
50	Remote ischemic preconditioning protects human neural stem cells from oxidative stress. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 1353-1361.	4.9	10
51	Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. Anticancer Research, 2017, 37, 5215-5223.	1.1	10
52	Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. American Journal of Translational Research (discontinued), 2014, 6, 169-78.	0.0	10
53	Neurod4 converts endogenous neural stem cells to neurons with synaptic formation after spinal cord injury. IScience, 2021, 24, 102074.	4.1	9
54	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. Immunotherapy, 2016, 8, 1393-1404.	2.0	8

#	Article	IF	CITATIONS
55	Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma. Cell Reports, 2019, 26, 2274-2281.e5.	6.4	8
56	Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Cancer Research, 2021, 81, 4861-4873.	0.9	7
57	Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, platinum-based chemotherapy, and radiotherapy: a single-institution study. Journal of Neurosurgery, 2020, , 1-9.	1.6	7
58	The Aftercare Survey: Assessment and intervention practices after brain tumor surgery in Europe. Neuro-Oncology Practice, 2022, 9, 328-337.	1.6	7
59	Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions. Frontiers in Neurology, 2022, 13, .	2.4	7
60	Rapid sensitive analysis of <i>IDH1</i> mutation in lower-grade gliomas by automated genetic typing involving a quenching probe. Cancer Investigation, 2016, 34, 12-15.	1.3	6
61	Spontaneous Tumor Regression of Intracranial Solitary Fibrous Tumor Originating From the Medulla Oblongata: A Case Report and Literature Review. World Neurosurgery, 2019, 130, 400-404.	1.3	6
62	Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Brain Tumor Pathology, 2022, 39, 14-24.	1.7	6
63	Characterization of Intraoperative Motor Evoked Potential Monitoring for Surgery of the Pediatric Population with Brain Tumors. World Neurosurgery, 2018, 119, e1052-e1059.	1.3	5
64	Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma. Molecules, 2019, 24, 3046.	3.8	5
65	Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. Journal of Neuro-Oncology, 2020, 148, 17-27.	2.9	5
66	Posterior Cerebral Artery Reconstruction by In-Situ Bypass with Superior Cerebellar Artery via Occipital Transtentorial Approach. World Neurosurgery, 2019, 126, 24-29.	1.3	4
67	Trautmann-focused mastoidectomy for a simple, safe presigmoid approach: technical note. Journal of Neurosurgery, 2021, 134, 843-847.	1.6	4
68	Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas. Journal of Neuro-Oncology, 2012, 106, 209-211.	2.9	3
69	Intraoperative seizure outcome of levetiracetam combined with perampanel therapy in patients with glioma undergoing awake brain surgery. Journal of Neurosurgery, 2021, 135, 998-1007.	1.6	3
70	Prognostic model of lower grade gliomas Journal of Clinical Oncology, 2015, 33, 2038-2038.	1.6	1
71	Survival Benefit of Supratotal Resection in a Long-term Survivor of <i>IDH</i> -wildtype Glioblastoma: A Case Report and Literature Review. NMC Case Report Journal, 2021, 8, 747-753.	0.5	1

72 Glioma-Initiating Cells: Interferon Treatment. , 2012, , 99-106.

#	Article	IF	CITATIONS
73	Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review. Neuro-Oncology Advances, 2020, 2, vdaa101.	0.7	0
74	Genetically-Engineered Neural Stem Cell Therapy for Spinal Cord Injury. Spinal Surgery, 2011, 25, 84-87.	0.0	0
75	Glioma-Initiating Cells: Interferon Treatment. , 2011, , 269-276.		0
76	The Basics of Glioma Surgery. Japanese Journal of Neurosurgery, 2012, 21, 937-942.	0.0	0
77	Abstract 2406: Intra-tumoral heterogeneity of PDGFRA / MET gain in WHO grade II diffuse astrocytomas , 2013, , .		0
78	Potential biomarkers for pseudoprogression in malignant glioma Journal of Clinical Oncology, 2013, 31, e13012-e13012.	1.6	0
79	Abstract 2229: Whole exome sequencing reveals the landscape of gene mutations and evolution in low-grade glioma. , 2014, , .		Ο
80	The landscape and clonal architecture in lower grade glioma Journal of Clinical Oncology, 2015, 33, 2008-2008.	1.6	0
81	Abstract 4751: Genetic subtype-specific prognostic significance of genetic alterations in lower-grade gliomas. , 2016, , .		0
82	Pathogenesis of Diffuse Low-Grade Gliomas. , 2017, , 111-117.		0
83	Awake Surgery for Brain Tumors to Preserve Motor, Language, and Neurocognitive Functions. The Japanese Journal of Rehabilitation Medicine, 2019, 56, 613-617.	0.0	0
84	Serum Concentration of Ropivacaine After Repeated Administration to Several Parts of the Head During Awake Craniotomy: A Prospective Cohort Study. Frontiers in Medicine, 2022, 9, .	2.6	0